Orbital Myeloma and Plasmacytoma: An Australian Study.
Journal
Ophthalmic plastic and reconstructive surgery
ISSN: 1537-2677
Titre abrégé: Ophthalmic Plast Reconstr Surg
Pays: United States
ID NLM: 8508431
Informations de publication
Date de publication:
10 Sep 2024
10 Sep 2024
Historique:
medline:
10
9
2024
pubmed:
10
9
2024
entrez:
10
9
2024
Statut:
aheadofprint
Résumé
The purpose of this study was to provide Australian data on the clinical and radiological features and outcomes in patients with orbital plasmacytomas. Multicentre retrospective review of orbital plasmacytoma and orbital involvement in multiple myeloma (MM) from 2005 to 2022 in Australia. Twenty-one participants were identified. The median age was 62 years (range 34-88 years), and 11 (52%) were females. Eighteen (84%) had a known diagnosis of MM prior to their orbital presentation, with all patients eventually being diagnosed with systemic MM. Thirteen (72%) were receiving active treatment for systemic myeloma on presentation, while 3 (17%) were in remission. All but 1 had unilateral orbital involvement (n = 20, 95%). Common presenting symptoms and signs were decreased visual acuity (n = 13, 62%), proptosis (n = 11, 52%), limited motility (n = 15, 71%), and optic neuropathy (n = 5, 24%). Radiologically, 15 (71%) involved the superotemporal orbit, 7 (33%) inferotemporal orbit, and 16 (76%) involved ≥1 extraocular muscle. Sixteen (76%) were biopsied and confirmed orbital plasmacytoma on histopathology. Treatment modalities included intravenous and oral steroids (n = 7, 33%), chemotherapy (n = 9, 43%), radiotherapy (n = 13, 62%), stem cell transplant (n = 3, 14%), and surgical debulking and decompression (n = 3, 14%). Mortality was high, with 15 (71%) having MM-related mortality. This is the largest cohort of Australian data on orbital plasmacytomas. Most patients have a diagnosis of systemic MM at presentation. It is crucial to recognize and treat these patients early due to a poor systemic prognosis.
Identifiants
pubmed: 39254970
doi: 10.1097/IOP.0000000000002777
pii: 00002341-990000000-00468
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc.
Déclaration de conflit d'intérêts
The authors have no financial or conflicts of interest to disclose.
Références
Van De Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet 2021;397:410–427.
Padala SA, Barsouk A, Barsouk A, et al. Epidemiology, staging, and management of multiple myeloma. Med Sci 2021;9:3.
Huang J, Chan SC, Lok V, et al.; Non-communicable Disease Global Health Research Group, Association of Pacific Rim Universities. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol 2022;9:e670–e677.
Chin KJ, Kempin S, Milman T, et al. Ocular manifestations of multiple myeloma: three cases and a review of the literature. Optometry 2011;82:224–230.
Beksac M, Seval GC, Kanellias N, et al. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. Haematologica 2020;105:201–208.
Shields JA, Shields CL, Scartozzi R. Survey of 1264 patients with orbital tumors and simulating lesions. Ophthalmology 2004;111: 997–1008.
Burkat CN, Van Buren JJ, Lucarelli MJ. Characteristics of orbital multiple myeloma: a case report and literature review. Surv Ophthalmol 2009;54:697–704.
Thuro BA, Sagiv O, Shinder R, et al. Clinical presentation and anatomical location of orbital plasmacytomas. Ophthalmic Plast Reconstr Surg 2018;34:258–261.
Aboud N, Sullivan T, Whitehead K. Primary extramedullary plasmacytoma of the orbit. Aust N Z J Ophthalmol 1995;23:235–239.
Zloto O, Vahdani K, Stack R, et al. Periocular presentation of solitary plasmacytomas and multiple myeloma. Ophthalmic Plast Reconstr Surg 2022;38:180–184.
Wang SSY, Lee MB, George A, et al. Five cases of orbital extramedullary plasmacytoma: diagnosis and management of an aggressive malignancy. Orbit 2019;38:218–225.
Bladé J, Beksac M, Caers J, et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J 2022;12:45.
Permaisuari N, Anggraini N, Mahyuddin M, et al. A case series of aggressive orbital plasmacytomas. Ocul Oncol Pathol 2022;8:197–202.
Fujino M. The histopathology of myeloma in the bone marrow. J Clin Exp Hematop 2018;58:61–67.
Pozdnyakova O, Morgan EA, Li B, et al. Patterns of expression of CD56 and CD117 on neoplastic plasma cells and association with genetically distinct subtypes of plasma cell myeloma. Leuk Lymphoma 2012;53:1905–1910.
Kapoor P, Greipp PT, Morice WG, et al. Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br J Haematol 2008;141:135–148.
Yavasoglu I, Sargin G, Kadikoylu G, et al. Immunohistochemical evaluation of CD20 expression in patients with multiple myeloma. Revista brasileira de hematologia e hemoterapia 2015;37:34–37.
Jian Y, Zhang Z, Zhou H, et al. CD20 expression: a risk stratification factor for newly diagnosed multiple myeloma with t(11;14). Front Oncol 2022;12:1061438.
Law MF, Chan HN, Leung C, et al. Marginal zone B-cell lymphoma mimicking extramedullary plasmacytoma and the clinical outcome after treatment. Arch Med Sci 2017;3:698–701.
An G, Xu Y, Shi L, et al. t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome. Leuk Res 2013;37:1251–1257.
Cavo M, Rajkumar SV, Palumbo A, et al.; International Myeloma Working Group. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011;117:6063–6073.
Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 2014;32:587–600.
Kumar SK, Callander NS, Hillengass J, et al. NCCN guidelines insights: multiple myeloma, version 1.2020. J Natl Compr Canc Netw 2019;17:1154–1165.
Rosiñol L, Beksac M, Zamagni E, et al. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol 2021;194:496–507.
Greipp PR, Miguel JS, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412–3420.
Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 2015;33:2863–2869.